GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulse Biosciences Inc (FRA:6L8) » Definitions » EV-to-EBIT

Pulse Biosciences (FRA:6L8) EV-to-EBIT : -17.64 (As of Jun. 07, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Pulse Biosciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Pulse Biosciences's Enterprise Value is €727.32 Mil. Pulse Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-41.24 Mil. Therefore, Pulse Biosciences's EV-to-EBIT for today is -17.64.

The historical rank and industry rank for Pulse Biosciences's EV-to-EBIT or its related term are showing as below:

FRA:6L8' s EV-to-EBIT Range Over the Past 10 Years
Min: -17.72   Med: -4.08   Max: -0.6
Current: -17.72

During the past 10 years, the highest EV-to-EBIT of Pulse Biosciences was -0.60. The lowest was -17.72. And the median was -4.08.

FRA:6L8's EV-to-EBIT is ranked worse than
100% of 448 companies
in the Medical Devices & Instruments industry
Industry Median: 19.55 vs FRA:6L8: -17.72

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Pulse Biosciences's Enterprise Value for the quarter that ended in Mar. 2024 was €422.31 Mil. Pulse Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-41.24 Mil. Pulse Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -9.77%.


Pulse Biosciences EV-to-EBIT Historical Data

The historical data trend for Pulse Biosciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulse Biosciences EV-to-EBIT Chart

Pulse Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.53 -12.23 -6.83 -2.06 -14.94

Pulse Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.98 -7.55 -4.63 -14.94 -10.38

Competitive Comparison of Pulse Biosciences's EV-to-EBIT

For the Medical Instruments & Supplies subindustry, Pulse Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulse Biosciences's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pulse Biosciences's EV-to-EBIT falls into.



Pulse Biosciences EV-to-EBIT Calculation

Pulse Biosciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=727.316/-41.242
=-17.64

Pulse Biosciences's current Enterprise Value is €727.32 Mil.
Pulse Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-41.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pulse Biosciences  (FRA:6L8) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Pulse Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-41.242/422.307829168
=-9.77 %

Pulse Biosciences's Enterprise Value for the quarter that ended in Mar. 2024 was €422.31 Mil.
Pulse Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-41.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pulse Biosciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Pulse Biosciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulse Biosciences (FRA:6L8) Business Description

Traded in Other Exchanges
Address
3957 Point Eden Way, Hayward, CA, USA, 94545
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.

Pulse Biosciences (FRA:6L8) Headlines

No Headlines